Navigation Links
Free Download: Two Impressive Case Studies on Drug Delivery Discoveries

SHANGHAI, Sept. 4, 2013 /PRNewswire/ -- Organized by CPhI Conferences, The 3rd NDDS & Clinical Trial Management China 2013, will take place on 27th-28th November at Sheraton HongKou, Shanghai. This year's edition will deliver themes which will drive cross-industry co-operation, highlight the latest market trends, showcase advances in both technique and methodology and provide an effective business networking environment for the conference's participants. The two-day conference will include 3 chapters: Drug discovery and research fulfillments, Novel pathway for future drug delivery solutions and Biotherapeutic drug delivery towards clinical science development. There will be 16 professional presentations and 2 panel discussions, to explore the commercial value, techniques, requirements and clinical science of NDDS. To download the full agenda, please log on to

Meanwhile, the organizer shared two excellent presentations with us about the medical devices industry. The first one was "Oral controlled release dosage form design and case study" by Andy Lu, the General Manager of Shanghai Aucta Pharmaceuticals Co., Ltd. In his speech, he discussed factors for formulation design, formulation and technology selection, formulation evaluation and a few fantastic case studies as well. The second was "Integration of  Nano-and Amorphous Solid Dispersion Formulations into Drug Discovery", by Yaling Wang, the Basic Pharmaceutical Sciences director of Merck Sharp & Dohme Corp. In her speech, she touched on formulation challenges in drug discovery, enhancement of dissolution/solubility limited exposure, nano-suspension formulation and much more. If you are interested in those topics, please CLICK HERE for a free download.

Please click on the following link if the download was unsuccessful:

Media Contact

Ms. Tracy Cui
Tel: +86-21-6157 3919
Fax:+86-21-6157 7299



SOURCE CPhI Conferences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Recognizes ResearchDx for Its Impressive Performance in the Companion Diagnostics Sector
2. National Pharmaceutical Council Studies New Formulary Decision-Making Tool
3. Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
4. Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
5. Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
6. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
9. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
10. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
11. ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein
Post Your Comments:
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
Breaking Medicine News(10 mins):